文献速递细菌感染、耐药与抗菌药物

抗生素耐药与复发性菌血症风险

Antibiotic Resistance and the Risk of Recurrent Bacteremia.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究基于荷兰2008-2017年血液分离菌耐药监测数据,量化耐药与复发性菌血症(4-30天)的关联。结果显示,对多种抗生素非敏感的首发菌血症与复发风险升高相关,但荷兰每年归因于耐药的多余复发事件估计仅40例。

要点

  • 单药/共非敏感的首发菌血症复发风险均高于敏感株,肠杆菌科共非敏感RR达5.2。
  • 敏感首发后发生非敏感复发的风险最高仅0.4%(假单胞菌)。
  • 荷兰每年归因于耐药的多余复发性菌血症估计约40例,整体负担有限。

核心结论

  • 抗生素非敏感与复发性菌血症风险升高持续相关,但荷兰每年额外复发事件估计仅40例,负担有限。

研究设计与样本

  • 基于荷兰2008-2017年抗菌药物耐药监测系统的血液分离菌药敏数据,纳入首次及首次复发(4-30天)菌血症发作。

主要发现

  • 肠杆菌科单非敏感和共非敏感vs敏感的首发后复发RR分别为1.7(95%CI 1.5-2.0)和5.2(95%CI 2.1-12.4)。
  • 假单胞菌单非敏感和共非敏感vs敏感的复发RR分别为1.3(95%CI 0.5-3.1)和5.0(95%CI 2.9-8.5)。
  • 肠球菌单非敏感和共非敏感vs敏感的复发RR分别为1.4(95%CI 1.2-1.7)和1.6(95%CI 0.6-4.2)。
  • MRSA vs MSSA的复发RR为1.6(95%CI 1.1-2.4)。
  • 敏感首发后发生非敏感复发的风险最高为0.4%(假单胞菌)。

关键数值与推荐

  • 复发定义为首次菌血症后4-30天内的再次发作。
  • 耐药分类包括对三代头孢±碳青霉烯类(肠杆菌科)、头孢他啶±碳青霉烯类(假单胞菌)、氨基青霉素±万古霉素(肠球菌)非敏感,及MRSA/MSSA。

临床怎么用

  • 对耐药非敏感首发菌血症患者应警惕4-30天内复发风险,尤其肠杆菌科共非敏感者。
  • 敏感首发后非敏感复发风险低,但假单胞菌等特定菌仍需关注。
  • 荷兰耐药归因复发负担有限,提示耐药对复发的影响因地区流行病学而异。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct health effects of antibiotic resistance are difficult to assess. We quantified the risk of recurrent bacteremia associated with resistance. METHODS: We extracted antimicrobial susceptibility testing data on blood isolates from the Dutch surveillance system for antimicrobial resistance between 2008 and 2017. First and first recurrent (4-30 days) bacteremia episodes were categorized as susceptible, single nonsusceptible, or co-nonsusceptible to third-generation cephalosporins without or with carbapenems (Enterobacteriaceae), ceftazidime without or with carbapenems (Pseudomonas species), aminopenicillins without or with vancomycin (Enterococcus species), or as methicillin-sensitive/-resistant S. aureus (MSSA/MRSA). We calculated risks of recurrent bacteremia after nonsusceptible vs susceptible first bacteremia, estimated the crude population attributable effect of resistance for the Netherlands, and calculated risks of nonsusceptible recurrent bacteremia after a susceptible first episode. RESULTS: Risk ratios for recurrent bacteremia after a single- and co-nonsusceptible first episode, respectively, vs susceptible first episode, were 1.7 (95% confidence interval [CI], 1.5-2.0) and 5.2 (95% CI, 2.1-12.4) for Enterobacteriaceae, 1.3 (95% CI, 0.5-3.1) and 5.0 (95% CI, 2.9-8.5) for Pseudomonas species, 1.4 (95% CI, 1.2-1.7) and 1.6 (95% CI, 0.6-4.2) for Enterococcus species, and 1.6 (95% CI, 1.1-2.4) for MRSA vs MSSA. The estimated population annual number of recurrent bacteremias associated with nonsusceptibility was 40. The risk of nonsusceptible recurrent bacteremia after a susceptible first episode was at most 0.4% (Pseudomonas species). CONCLUSIONS: Although antibiotic nonsusceptibility was consistently associated with higher risks of recurrent bacteremia, the estimated annual number of additional recurrent episodes in the Netherlands (40) was rather limited.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Woudt SHS, de Greeff SC, Schoffelen AF, et al. Antibiotic Resistance and the Risk of Recurrent Bacteremia. Clin Infect Dis. 2018. PMID: 29228127. doi:10.1093/cid/cix1076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。